# A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock

> **NCT03623529** · PHASE2 · UNKNOWN · sponsor: **La Jolla Pharmaceutical Company** · enrollment: 100 (estimated)

## Conditions studied

- Catecholamine-resistant Hypotension (CRH)
- Distributive Shock
- High Output Shock
- Septic Shock

## Interventions

- **DRUG:** LJPC-501 (angiotensin II)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03623529
- **Lead sponsor:** La Jolla Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08
- **Primary completion:** 2023-03
- **Final completion:** 2023-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03623529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03623529, "A Study of LJPC-501 in Paediatric Patients With Hypotension Associated With Distributive or Vasodilatory Shock". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03623529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*